Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. IBM
8. KNX
9. AMD
10. INTC

Go back to Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
(NASDAQ: CRNX) Delayed: 83.66 -0.06 (0.07%)
Previous Close $83.72    52 Week High $ 
Open $83.78    52 Week Low $ 
Day High $83.79    P/E N/A 
Day Low $83.65    EPS $ 
Volume 3,222,934